DUBLIN--(BUSINESS WIRE)--The 'Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027' report has been added to ResearchAndMarkets.com's offering.

都柏林--（商业新闻短讯）--“全球PROTAC靶向蛋白质降解剂市场机遇与临床试验洞察2027”报告已添加到ResearchAndMarkets.com的产品中。

First conceptualized in the early 2000s, proteolysis-targeting chimeras (PROTACs) are emerging as a transformative approach in targeted therapies. By harnessing the body's natural ubiquitin-proteasome system, PROTACs selectively eliminate specific proteins implicated in various diseases, particularly those that have been historically deemed undruggable.

蛋白水解靶向嵌合体（PROTACs）在21世纪初首次被概念化，正在成为靶向治疗中的一种变革性方法。通过利用人体的天然泛素-蛋白酶体系统，PROTAC选择性地消除与各种疾病有关的特定蛋白质，特别是那些历史上被认为不可治疗的蛋白质。

This innovative therapeutic modality is gaining traction in both academic and industrial settings, with a focus on addressing significant gaps in treatment options for patients with complex diseases..

这种创新的治疗方式在学术和工业环境中都越来越受欢迎，重点是解决复杂疾病患者治疗选择的重大差距。。

Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027 Report Finding & Inclusions:

全球PROTAC靶向蛋白质降解剂市场机遇与临床试验洞察2027报告发现与包含：

First PROTAC Drug Approval Expected By 2027

第一批PROTAC药物有望于2027年获得批准

Global & Regional PROTAC Drug Market Trends Insight

全球和地区PROTAC药物市场趋势洞察

First 12 Months & First 5 Years Market Size Estimates Since Approval

自批准以来的前12个月和前5年市场规模估计

Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase: > 90 Drugs

全球PROTAC药物临床试验洞察公司、国家、适应症和阶段：>90种药物

FDA Fast Track & Orphan Drug Status Insight By Company & Indication

FDA快速通道和孤儿药状态洞察（按公司和适应症）

Comprehensive Insight On PROTAC Technology Platforms: 10 Platforms

对PROTAC技术平台的全面了解：10个平台

Global PROTAC Drug Market Trends By Indications

全球PROTAC药物市场趋势（按适应症）

Competitive Landscape

竞争格局

PROTACs function through a unique mechanism that comprises three essential components: a targeting ligand, an E3 ligase ligand, and a linker. The targeting ligand binds specifically to the protein of interest (POI), which often plays a crucial role in disease pathology. This can include proteins associated with cancer or neurodegenerative disorders.

PROTAC通过一种独特的机制起作用，该机制包含三个基本成分：靶向配体，E3连接酶配体和接头。靶向配体特异性结合目标蛋白（POI），该蛋白通常在疾病病理学中起关键作用。。

The E3 ligase ligand links the PROTAC to an E3 ligase, an enzyme that facilitates the attachment of ubiquitin molecules to proteins. Once the PROTAC simultaneously binds to the POI and the E3 ligase, it catalyzes the transfer of ubiquitin, marking the target for degradation by the proteasome. This mechanism allows for a more effective and precise intervention in disease processes compared to traditional small molecule inhibitors, which often only inhibit protein function without promoting degradation..

E3连接酶配体将PROTAC连接到E3连接酶，E3连接酶是一种促进泛素分子与蛋白质连接的酶。一旦PROTAC同时与POI和E3连接酶结合，它就会催化泛素的转移，标志着蛋白酶体降解的目标。与传统的小分子抑制剂相比，这种机制可以更有效和精确地干预疾病过程，而传统的小分子抑制剂通常只抑制蛋白质功能而不促进降解。。

The most prominent application of PROTACs is in cancer treatment. Cancer involves a complex interplay of proteins that contribute to tumor growth, progression, metastasis, and resistance to existing therapies. PROTACs are being developed to target and degrade a variety of key proteins, including KRAS, BRAF, cyclin-dependent kinases, and hormone receptors like estrogen and androgen receptors.

PROTAC最突出的应用是癌症治疗。癌症涉及蛋白质的复杂相互作用，这些蛋白质有助于肿瘤的生长，进展，转移和对现有疗法的抵抗。正在开发PROTAC以靶向和降解多种关键蛋白，包括KRAS，BRAF，细胞周期蛋白依赖性激酶以及雌激素和雄激素受体等激素受体。

Among the candidates in clinical trials, Vepdegestrant (ARV-471), an estrogen receptor degrader developed by Arvinas, stands out. As of October 2024, Vepdegestrant is undergoing phase 3 clinical trials for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer..

在临床试验的候选药物中，Arvinas开发的雌激素受体降解剂Vepdegestrant（ARV-471）脱颖而出。截至2024年10月，Vepdegestrant正在进行治疗雌激素受体阳性，人表皮生长因子受体2阴性（ER+/HER2-）乳腺癌的3期临床试验。。

This makes it the most advanced PROTAC candidate in the global pipeline, potentially paving the way to become the first PROTAC on the market by the end of this decade.

这使其成为全球管道中最先进的PROTAC候选者，可能为在本世纪末成为市场上第一个PROTAC铺平道路。

In addition to Vepdegestrant, Arvinas is also conducting a Phase 1/2 clinical trial for Bavdegalutamide (ARV-110), a PROTAC targeting the androgen receptor in patients with metastatic castration-resistant prostate cancer. This dual approach highlights the potential of PROTACs to address multiple facets of cancer biology effectively..

除Vepdegestrant外，Arvinas还正在进行一项针对转移性去势抵抗性前列腺癌患者雄激素受体的PROTAC巴伐鲁胺（ARV-110）的1/2期临床试验。这种双重方法突出了PROTAC有效解决癌症生物学多个方面的潜力。。

Beyond oncology, the application of PROTACs is expanding into the realm of autoimmune and inflammatory disorders. Researchers are exploring their potential to degrade key proteins involved in inflammatory signaling pathways. Notably, proteins from the IRAK family, especially IRAK4, and BTK kinase are being targeted for PROTAC development in these areas.

除了肿瘤学之外，PROTAC的应用正在扩展到自身免疫和炎症性疾病的领域。研究人员正在探索它们降解炎症信号通路中关键蛋白的潜力。值得注意的是，来自IRAK家族的蛋白质，尤其是IRAK4和BTK激酶，正在这些领域成为PROTAC发展的目标。

While most candidates in this category are still in early phases, with few like HSK-40118 and KT-474 currently in clinical trials, ongoing research promises to uncover more viable options in the future..

虽然这一类别的大多数候选人仍处于早期阶段，目前很少有像HSK-40118和KT-474这样的候选人正在进行临床试验，但正在进行的研究有望在未来发现更多可行的选择。。

The commercial landscape for PROTACs is burgeoning, characterized by strategic collaborations aimed at accelerating the discovery and development of new PROTAC-based therapies. In January 2024, Galapagos and BridGene Biosciences announced a strategic partnership to develop novel precision medicines targeting clinically validated oncology targets.

PROTAC的商业前景正在蓬勃发展，其特点是旨在加速基于PROTAC的新疗法的发现和开发的战略合作。2024年1月，加拉帕戈斯和BridGene Biosciences宣布建立战略伙伴关系，开发针对临床验证肿瘤学目标的新型精密药物。

This collaboration aims to leverage both companies' expertise to enhance the development pipeline of PROTACs. In August 2024, they expanded their agreement to include efforts on developing a selective oral SMARCA2 PROTAC in precision oncology, underscoring the collaborative spirit in this emerging field..

。2024年8月，他们扩大了协议范围，包括在精准肿瘤学中开发选择性口服SMARCA2 PROTAC的努力，强调了这一新兴领域的合作精神。。

The market for PROTACs is anticipated to grow significantly, driven by advancements in research and increasing investments in drug development. The unique mechanism of action and the ability to target previously undruggable proteins position PROTACs as a promising addition to the therapeutic arsenal against complex diseases..

受研究进展和药物开发投资增加的推动，PROTAC市场预计将大幅增长。独特的作用机制和靶向先前不可药用蛋白质的能力使PROTAC成为针对复杂疾病的治疗武器库的有希望的补充。。

As the PROTAC field continues to evolve, its clinical and commercial prospects look bright. The promising early results from clinical trials and the strategic partnerships being formed indicate that PROTACs could soon revolutionize treatment paradigms for various diseases, particularly cancer and autoimmune disorders.

随着PROTAC领域的不断发展，其临床和商业前景看起来很光明。临床试验和正在形成的战略伙伴关系的有希望的早期结果表明，PROTAC可以很快彻底改变各种疾病的治疗模式，特别是癌症和自身免疫性疾病。

With ongoing research and development, PROTACs are set to become a cornerstone of targeted therapy, offering new hope to patients and filling critical gaps in treatment. As we move toward the latter half of this decade, the landscape of drug development is likely to be significantly reshaped by the success of PROTAC technology..

随着不断的研究和开发，PROTAC将成为靶向治疗的基石，为患者提供新的希望，填补治疗中的关键空白。随着我们进入本十年的后半期，PROTAC技术的成功可能会大大改变药物开发的前景。。

Report Scope

报告范围

Key Segments

关键细分市场

By Indication

根据指示

By Region

按地区

Technology Platforms

技术平台

Therapeutic Areas

治疗领域

Cancer

癌症

Infectious Diseases

传染病

Autoimmune & Inflammatory Diseases and others

自身免疫性和炎性疾病及其他

Countries Covered

涵盖的国家/地区

US

美国

China

中国

South Korea

韩国

Report Coverage

报告覆盖范围

Mechanism of Action

作用机制

Potential in Cancer

癌症的潜力

Comprehensive Clinical Drugs Insight

全面的临床药物洞察

Current Trends and Future Opportunities

当前趋势和未来机遇

Companies Covered Include:

涵盖的公司包括：

Arvinas

阿文

EnhancedBio

增强型IO

Uppthera

Uppthera

TYK Medicine

TYK医学

Axter Therapeutics

Axter Therapeutics公司

Key Topics Covered:

涵盖的关键主题：

1. Introduction To PROTAC Technology

1、PROTAC技术简介

1.1 Overview Of PROTAC Technology

1.1 PROTAC技术概述

1.2 Development & Evolution of PROTACs

1.2 PROTAC的发展和演变

2. PROTAC Therapies Potential In Cancer Therapeutics

2.PROTAC疗法在癌症治疗中的潜力

2.1 Importance As Targeted Therapy

2.1作为靶向治疗的重要性

2.2 Comparison With Conventional Treatment Methods

2.2与常规处理方法的比较

3. Clinical Overview of PROTAC Technology

3、PROTAC技术临床概述

3.1 Components Of PROTAC Molecules

3.1 PROTAC分子的成分

3.2 Mechanism Of Action

3.2作用机制

4. Global PROTAC Drug Market Trends Insight

4、全球PROTAC药物市场趋势洞察

4.1 Current Market Overview

4.1当前市场概况

4.2 Future Clinical & Commercial Opportunities

4.2未来的临床和商业机会

5. Global PROTAC Drug Market Trends By Region

5、全球PROTAC药物市场趋势（按地区）

5.1 US

5.1美国

5.2 South Korea

5.2韩国

5.3 China

5.3中国

6. Global PROTAC Drugs Clinical Trials Insight Overview

全球PROTAC药物临床试验洞察概述

6.1 By Company

6.1由公司提供

6.2 By Country

6.2按国家

6.3 By Patient Segment

6.3按患者细分

6.4 By Phase

6.4按阶段

6.5 By Orphan & Fast Track Status

6.5按孤儿和快速通道状态

7. Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase

7、全球PROTAC药物临床试验洞察（按公司、国家、适应症和阶段）

7.1 Research

7.1研究

7.2 Preclinical

7.2临床前

7.3 Phase I

7.3第一阶段

7.4 Phase I/II

7.4第一/第二阶段

7.5 Phase II

7.5第二阶段

7.6 Phase III

7.6第三阶段

8. Global PROTAC Drug Market Trends By Indication

全球PROTAC药物市场趋势（按适应症）

8.1 Cancer

8.2 Infectious Diseases

8.2传染病

8.3 Neurodegenerative diseases

8.3神经退行性疾病

8.4 Autoimmune & Inflammatory Diseases

8.4自身免疫性和炎性疾病

8.5 Cardiovascular Diseases

9. PROTAC Technology Platforms

9、PROTAC技术平台

10. Global PROTAC Drugs Market Dynamics & Outlook

10.1 Drivers & Opportunities

10.1驱动因素和机会

10.2 Challenges & Restraints

10.2挑战和限制

11. Competitive Landscape

11、竞争格局

Arvinas

阿文

Axter Therapeutics

Axter Therapeutics公司

Beactica

Beactica公司

BioTheryX

BioTheryX

EnhancedBio

增强型IO

Suzhou Kintor Pharmaceuticals

苏州金拓药业

Monte Rosa Therapeutics

Monte Rosa治疗学

TYK Medicine

TYK医学

Ubix Therapeutics

Ubix治疗学

Uppthera

Uppthera

For more information about this report visit https://www.researchandmarkets.com/r/9px1x0

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/9px1x0

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。